Raj Reddy
Chief Executive Officer Canary Cure Therapeutics
Seminars
Wednesday 3rd June 2026
Panel Discussion: Exploring the Future of Extrahepatic LNPs to Overcome Delivery Barriers, Expand Therapeutic Reach, & Unlock Novel Disease Treatments
2:15 pm
- What are the remaining barriers for achieving efficient, organ-specific delivery to difficult targets?
- Which design strategies and technologies are most promising for enabling precise extrahepatic targeting while minimizing liver accumulation?
- What unmet therapeutic needs could next-generation extrahepatic LNPs address to expand the RNA, gene editing, and cell therapy landscape?
Wednesday 3rd June 2026
Next Gen Novel Stealth Fusion LNP with an “Endosomal Bypass” Core: Obliterating the
12:15 pm
- Redefining the LNP Core (The “Active Fusion Core”): Introducing the Hyper-15™ Proteolipid Vehicle (PLV), a novel LNP active fusion core architecture embedded with a proprietary “Wedge & Motor” fusion engine. Unlike first-generation viral fusion proteins that rely on slow “hydrophobic insertion” loops, this platform utilizes a novel method to sterically displace membrane hydration, rendering the core mechanism insensitive to target lipid composition
- Bypassing the “Acidification Trap”: While standard LNPs lose >98% of cargo to endosomal degradation, Hyper-15™ completely bypasses the endocytic pathway. By forcing active, instantaneous fusion at the plasma membrane surface, we demonstrate the ability to achieve 100% cytosolic bioavailability of genetic payloads without requiring pH-dependent acidification or receptor upregulation
- Unlocking “Endocytically Quiet” Tissue: Presenting breakthrough efficacy data in Human Skeletal Muscle Myotubes and Adipocytes. We show how this mechanical fusion mechanism successfully transfects mature, non-dividing tissues that are impenetrable to standard LNPs, overcoming the industry’s longest-standing delivery bottleneck in metabolic and neuromuscular disease
